丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）合并感染患者的药物相互作用——回复 - Suppr

Suppr

超能文献

Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.

作者信息

Osinusi Anu, Townsend Kerry, Kottilil Shyam

机构信息

Institute of Human Virology, University of Maryland, Baltimore.

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.

出版信息

JAMA. 2015 Jul 14;314(2):186-7. doi: 10.1001/jama.2015.6621.

DOI:10.1001/jama.2015.6621

PMID:26172900

Abstract

摘要

相似文献

Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.

JAMA. 2015 Jul 14;314(2):186-7. doi: 10.1001/jama.2015.6621.

Drug-Drug Interactions in Patients Co-infected With HCV and HIV.

JAMA. 2015 Jul 14;314(2):186. doi: 10.1001/jama.2015.6618.

Are we hopefully very close to the end of HCV?

Turk J Gastroenterol. 2014 Apr;25(2):230-1. doi: 10.5152/tjg.2014.0009.

Hepatitis C and HIV co-infection: closing the gaps.

JAMA. 2015;313(12):1217-8. doi: 10.1001/jama.2015.1111.

Therapy for hepatitis C--the costs of success.

N Engl J Med. 2014 Apr 17;370(16):1552-3. doi: 10.1056/NEJMe1401508. Epub 2014 Apr 11.

A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.

Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2.

Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.

J Antimicrob Chemother. 2017 Oct 1;72(10):2955-2958. doi: 10.1093/jac/dkx222.

Viral hepatitis: new hepatitis C therapies-a medical pick and mix.

Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):329. doi: 10.1038/nrgastro.2014.64. Epub 2014 Apr 29.

New Indications for Harvoni.

Med Lett Drugs Ther. 2016 Jan 4;58(1485):6.

Assessing a broader user base for new HCV drug.

Lancet Infect Dis. 2015 Apr;15(4):383. doi: 10.1016/S1473-3099(15)70119-2.

引用本文的文献

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.

Eur J Clin Pharmacol. 2021 Sep;77(9):1297-1307. doi: 10.1007/s00228-021-03108-x. Epub 2021 Mar 4.

Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.

Expert Opin Pharmacother. 2016;17(5):743-9. doi: 10.1517/14656566.2016.1157580. Epub 2016 Mar 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.

JAMA. 2015 Jul 14;314(2):186-7. doi: 10.1001/jama.2015.6621.

Drug-Drug Interactions in Patients Co-infected With HCV and HIV.

JAMA. 2015 Jul 14;314(2):186. doi: 10.1001/jama.2015.6618.

Are we hopefully very close to the end of HCV?

Turk J Gastroenterol. 2014 Apr;25(2):230-1. doi: 10.5152/tjg.2014.0009.

Hepatitis C and HIV co-infection: closing the gaps.

JAMA. 2015;313(12):1217-8. doi: 10.1001/jama.2015.1111.

Therapy for hepatitis C--the costs of success.

N Engl J Med. 2014 Apr 17;370(16):1552-3. doi: 10.1056/NEJMe1401508. Epub 2014 Apr 11.

A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.

Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2.

Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.

J Antimicrob Chemother. 2017 Oct 1;72(10):2955-2958. doi: 10.1093/jac/dkx222.

Viral hepatitis: new hepatitis C therapies-a medical pick and mix.

Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):329. doi: 10.1038/nrgastro.2014.64. Epub 2014 Apr 29.

New Indications for Harvoni.

Med Lett Drugs Ther. 2016 Jan 4;58(1485):6.

Assessing a broader user base for new HCV drug.

Lancet Infect Dis. 2015 Apr;15(4):383. doi: 10.1016/S1473-3099(15)70119-2.

引用本文的文献

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.

Eur J Clin Pharmacol. 2021 Sep;77(9):1297-1307. doi: 10.1007/s00228-021-03108-x. Epub 2021 Mar 4.

Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.

Expert Opin Pharmacother. 2016;17(5):743-9. doi: 10.1517/14656566.2016.1157580. Epub 2016 Mar 16.